Robotic vs Laparoscopic Sleeve Gastrectomy for Obesity
(EARLY Trial)
Trial Summary
What is the purpose of this trial?
This will be a prospective, obesity-registry based, single-blind randomized controlled trial with a 1:1 allocation ratio. Specific inclusion criteria are all patients eligible to undergo a Laparoscopic sleeve gastrectomy (LSG) based on the current National Institute of Health (NIH) patient selection guidelines. Patients should be able to give consent, be deemed medically-cleared to undergo elective surgery, and tolerate general anesthesia. All enrollments and surgeries in this study will take place at the Cleveland Clinic Bariatric and Metabolic Institute. The study will consist of 2 interventions: laparoscopic sleeve gastrectomy (LSG) or robotic sleeve gastrectomy (RSG). The primary objective is early postoperative pain, but also surgeon ergonomics and patient quality of life will be compared. Additional outcomes include 30-day perioperative results, minor and major morbidities, serious adverse events, resolution of medical comorbidities, and weight loss in percent of excess weight lost (%EWL) at one year.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Robotic vs Laparoscopic Sleeve Gastrectomy for Obesity?
Research shows that both robotic and laparoscopic sleeve gastrectomy are effective for treating obesity, with laparoscopic sleeve gastrectomy being the more commonly used procedure. Robotic sleeve gastrectomy is an alternative that may offer technical advantages, especially in very obese patients.12345
Is robotic or laparoscopic sleeve gastrectomy safe for humans?
Both robotic and laparoscopic sleeve gastrectomy are generally considered safe for treating obesity, with studies showing no significant differences in complications between the two methods. However, there is limited evidence on long-term outcomes for robotic sleeve gastrectomy, and some studies suggest slightly higher reoperation rates for certain conditions.14678
How does robotic sleeve gastrectomy differ from laparoscopic sleeve gastrectomy for obesity?
Robotic sleeve gastrectomy (RSG) uses a robotic platform, like the da Vinci system, which may offer technical advantages in surgery, especially for very obese patients, compared to the more commonly used laparoscopic sleeve gastrectomy (LSG). While both aim to reduce stomach size to help with weight loss, the robotic approach is less frequently used and may provide more precision and control during the procedure.145910
Research Team
Ricard Corcelles Codina, MD
Principal Investigator
The Cleveland Clinic
Eligibility Criteria
This trial is for individuals eligible for bariatric surgery to treat obesity, as per NIH guidelines. Participants must be able to consent, be medically cleared for elective surgery, and handle general anesthesia. It's taking place at the Cleveland Clinic Bariatric and Metabolic Institute.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either laparoscopic or robotic sleeve gastrectomy
Postoperative Monitoring
Participants are monitored for early postoperative pain and other outcomes
Follow-up
Participants are monitored for resolution of medical comorbidities and weight loss
Treatment Details
Interventions
- Laparoscopic Sleeve Gastrectomy (Procedure)
- Robotic Sleeve Gastrectomy (Procedure)
Laparoscopic Sleeve Gastrectomy is already approved in Canada for the following indications:
- Obesity
- Severe obesity with comorbidities
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ricard Corcelles
Lead Sponsor